Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Leukemia

Texans show support for WR John Metchie following Acute Promyelocytic Leukemia diagnosis

Receiver John Metchie drew support from past and present Houston Texans following his announcement of his Acute Promyelocytic Leukemia diagnosis.

USA Today Sports Media Group

Twitter reacts to Leukemia diagnosis of Texans rookie WR John Metchie

Houston Texans rookie receiver John Metchie gathered an outpouring of support on Twitter following his diagnosis of Acute Promyelocytic Leukemia.

USA Today Sports Media Group

Texans rookie WR John Metchie III announces leukemia diagnosis

Houston Texans second-round pick John Metchie III has been diagnosed with acute promyelocytic leukemia

USA Today Sports Media Group

From analysis to the latest developments in health,
read the most diverse news in one place.

Texans Rookie John Metchie III Announces Leukemia Diagnosis

The Houston wide receiver is expected to miss the 2022 season.

Sports Illustrated

Texans rookie WR John Metchie diagnosed with Acute Promyelocytic Leukemia and likely to miss 2022 season

Houston Texans rookie receiver John Metchie announced his Acute Promyelocytic Leukemia diagnosis, and says he may miss the 2022 season.

USA Today Sports Media Group

John Metchie III diagnosed with Leukemia

Houston Texans rookie wide receiver John Metchie III announced he was diagnosed with a form of Leukemia.

USA Today Sports Media Group

Recap Of Friday's Biotech Catalysts - End Of The Day Summary

Bristol Myers Squibb (NYSE:BMY) received European Medicines Agency (EMA) Positive CHMP Opinion recommending approval for Opdualag (nivolumab and relatlimab) for treatment of patients with Unresectable or Metastatic Melanoma based on results from the Phase 2/3 RELATIVITY-047 trial. Bristol Myers shares traded in a range of $72.48 to $73.61 on a…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Ballymena boy diagnosed with leukemia after limping for weeks

"This has to be any parent's worst nightmare"

Belfast Live

Ducks Prospect Finished 2 1/2 Years of Leukemia Treatments

The 22-year-old rang the bell on Monday to officially signal the end of two-and-a-half years of chemo treatments.

Sports Illustrated

Stephen Bradley shaves his head for young son's charity fundraiser

His son Josh was diagnosed with Acute lymphocytic leukemia last month and the family have started a 'Shave your head' fundraising challenge

Dublin Live

Deadly Genetics: Gene Mutations May Be Source Of Deadly Blood Cancer

"Identifying a future risk of development of leukemia may ultimately offer the possibility of prevention."

Zenger

Why Precigen Shares Are Gaining Today

Precigen Inc (NASDAQ:PGEN) has agreed to sell its subsidiary Trans Ova Genetics, an animal reproductive technologies company, to URUS, a holding company with cooperative and private ownership. The deal consideration includes $170 million in upfront cash and up to $10 million earn-out based on the performance of Trans Ova in 2022 and 2023. …

Benzinga

ALX Oncology Shares Soar As FDA Grants Orphan Drug Status To Blood Cancer Candidate

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ALX Oncology Holdings’ (NASDAQ: ALXO) Evorpacept for the treatment of patients with acute myeloid leukemia (AML).

Benzinga

Boy's large vein turns out to be rare cancer which needs over 2,200 medical procedures

Seb, of Tring, Hertfordshire, was diagnosed with leukemia after a bold vein appeared running from his neck to his groin was actually a sign of cancer

Daily Mirror

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

HC Wainwright Believes This Cancer-Focused Stock Is Undervalued At $550M

HC Wainwright initiated coverage of Celularity Inc (NASDAQ:CELU) with a Buy rating and a price target of $15. HC Wainwright believes Celularity's current valuation of approximately $550 million is undervalued considering the upside potential of the company's platform and provides an attractive entry point for long-term investors. The analyst wrote that the company had…

Benzinga

BMO Capital Says Risk/Reward For This Gene Stock Assumes Clinical Success

BMO Capital initiated coverage on Beam Therapeutics Inc (NASDAQ:BEAM) with a Market Perform rating and a price target of 41. BMO writes that it appreciates the high potential of Beam's next-generation editing approach, but clinical validation is yet to be established. Preclinical base editing data point to a favorable benefit/risk profile. Also Read: Pfizer, Beam…

Benzinga

LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Cancer Program

LAVA Therapeutics N.V. (NASDAQ:LVTX) hosted a clinical update call focused on initial Phase 1/2a data for LAVA-051 in patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) at the American Society of Clinical Oncology and European Hematology Association meetings. "Although preliminary, these data support our view of LAVA-051 as a promising candidate…

Benzinga

Analysts Cuts Price Target On This Small Cap But Remain Bullish

Chardan analyst Matthew Barcus lowered the price target on Vincerx Pharma Inc (NASDAQ:VINC) to $4 from $11 and kept a Buy rating on the shares. The company announced a strategic update to focus on its Phase Ib development of lead program VIP152 in double-hit diffuse large B-cell lymphoma and chronic lymphocytic leukemia. It also…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

FDA Sounds Positive On Bluebird's One Gene Therapy But Doubts Another

The FDA signaled in briefing documents released that it may approve Bluebird bio Inc's (NASDAQ:BLUE) beti-cel gene therapy to treat β-thalassemia for those who require regular blood transfusions. The Prescription Drug User Fee Act (PDUFA) goal dates for beti-cel and eli-cel are August 19 and September 16. Bluebird bio's blood disorder treatment demonstrates "clinically meaningful"…

Zenger

Going For Gold: Metal Detector Couple Find Five Rare 14th Century Gold Coins In Field

A metal detectorist couple unearthed five rare 14th-century gold coins from the reign of Edward III in a field that could fetch up to £15,000 – and the find happened while one of them was suffering from leukemia.

Glasgow Live

Glasgow dad opens up as gymnast daughter's 'growing pains' lead to cancer diagnosis

Liv Dickson's determination to beat the disease has inspired her dad Allan to taken on a massive charity effort to raise money to help develop new treatments, and he will cycle the 3,500km Tour de France route next month.

WEKU

The youngest of the 10 people killed in the Buffalo shooting was laid to rest

Roberta Drury grew up in the Syracuse area and moved to Buffalo a decade ago to help tend to her brother in his fight against leukemia. She was remembered for her love for family and friends.

Benzinga

FDA Places Clinical Hold On Foghorn Therapeutics' Early-Stage Blood Cancer Trial

The FDA has instituted a clinical hold on Foghorn Therapeutics Inc's (NASDAQ:FHTX) Phase 1 dose-escalation study of FHD-286 in relapsed and/or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). The FDA initiated the partial clinical hold following the report of a recent death that occurred in a subject with potential differentiation syndrome. Differentiation…

Benzinga

Magenta Therapeutics Reveals Encouraging Interim Data From Lowest Dose Of MGTA-117 In Leukemia Trial

Magenta Therapeutics Inc (NASDAQ:MGTA) shared preliminary data from the Phase 1/2 dose-escalation trial of MGTA-117 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome with excess blasts. The data comes from a Cohort 1, evaluating the lowest dose of MGTA-117 (0.02 mg/kg). Three patients completed the safety evaluation period. A fourth patient with…

Nottingham Post

Nottingham couple forced to raise funds to treat daughter abroad

"Its pretty horrific all the time but the hope that this might be her cure is getting us through"

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.